3:27 PM
 | 
Nov 01, 2018
 |  BC Extra  |  Politics & Policy

FDA guides development of finite therapies to cure HBV

FDA released draft guidance Thursday to encourage development of finite, curative HBV treatments that have a low risk of virologic relapse and minimal risk of liver disease progression after treatment. FDA recommended developers use a two-pronged primary efficacy endpoint of sustained HBV DNA suppression off-treatment and HBV surface antigen (HBsAg) loss.

Current available treatments, including standard of care nucleoside...

Read the full 284 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >